Putative transport mechanism and intracellular fate of trans-1-amino-3- 18F-fluorocyclobutanecarboxylic acid in human prostate cancer

Journal of Nuclear Medicine

Volumn 52, Issue 5, 2011, Pages 822-829

  Okudaira, Hiroyuki ^a,b   Shikano, Naoto ^c   Nishii, Ryuichi ^d   Miyagi, Tohru ^a   Yoshimoto, Mitsuyoshi ^e   Kobayashi, Masato ^a   Ohe, Kazuyo ^a   Nakanishi, Takeo ^a   Tamai, Ikumi ^a   Namiki, Mikio ^a   Kawai, Keiichi ^a,f  

^a KANAZAWA UNIVERSITY   (Japan)

^b Amagasaki Front Building   (Japan)

^c IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^d UNIVERSITY OF FUKUI   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f UNIVERSITY OF FUKUI   (Japan)

Author keywords

Amino acid transporter; Anti FACBC; ASCT2; Prostate cancer

Indexed keywords

2 AMINO 2 NORBORNANECARBOXYLIC ACID; 2 METHYL 2 METHYLAMINOPROPIONIC ACID; AMINO ACID TRANSPORTER; ASC TRANSPORTER 2; CARBOXYLIC ACID DERIVATIVE; MESSENGER RNA; RADIOISOTOPE; SODIUM COUPLED NEUTRAL AMINO ACID TRANSPORTER; SODIUM ION; TRANS 1 AMINO 3 FLUOROCYCLOBUTANECARBOXYLIC ACID C 14; TRANS 1 AMINO 3 FLUOROCYCLOBUTANECARBOXYLIC ACID F 18; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL LEVEL; CONTROLLED STUDY; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

AMINO ACID TRANSPORT SYSTEM ASC; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CARBOXYLIC ACIDS; CELL LINE, TUMOR; CYCLOBUTANES; GENE EXPRESSION PROFILING; HUMANS; INTRACELLULAR SPACE; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 79955775731     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.086074     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Matsuda T, Saika K. Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, vol. IV-IX. Jpn J Clin Oncol. 2009;39:468-469.
3. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274-292. (Pubitemid 39365998)
4. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445. (Pubitemid 32207394)
5. 11C] methionine. J Nucl Med. 1987;28:1037-1040.
6. 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002;43:46-55.
7. Washburn LC, Sun TT, Anon JB, Hayes RL. Effect of structure on tumor specificity of alicyclic alpha-amino acids. Cancer Res. 1978;38:2271-2273. (Pubitemid 8390863)
8. Sordillo PP, DiResta GR, Fissekis J, et al. Tumor imaging with carbon-11 labeled alpha-aminoisobutyric acid (AIB) in patients with malignant melanoma. Am J Physiol Imaging. 1991;6:172-175.
9. 11C]-ACBC) for detecting recurrent brain tumors. Clin Positron Imaging. 1998;1:165-173.
10. 18F]1- amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331-338.
11. 18F]FACBC) with PET in renal carcinoma. Mol Imaging Biol. 2009;11:434-438.
12. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.
13. 18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med. 2007;48:46-55.
14. Bröer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev. 2008;88:249-286.
15. Palacín M, Estévez R, Bertran J, Zorzano A. Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev. 1998;78:969-1054. (Pubitemid 28491947)
16. Saier MH Jr, Daniels GA, Boerner P, Lin J. Neutral amino acid transport systems in animal cells: potential targets of oncogene action and regulators of cellular growth. J Membr Biol. 1988;104:1-20.
17. 18F-labeled amino acids for tumor imaging: comparison of in vitro and in vivo uptake of branched chain and cyclobutyl amino acids by 9L gliosarcoma tumor cells [abstract]. J Nucl Med. 2002;43(suppl):41P.
18. 18F]fluorocyclobutyl- 1-carboxylic acid as a potential positron emission tomography brain tumor imaging agent. Bioorg Med Chem. 2009;17:1982-1990.
19. 125I-3- iodo-α-methyl-L-tyrosine uptake in Chinese hamster ovary (CHO-K1) cells by tyrosine esters. Nucl Med Biol. 2010;37:189-196.
20. 125I]iodo- α-methyl-L-tyrosine into colon cancer DLD-1 cells: characterization and inhibitory effect of natural amino acids and amino acid-like drugs. Nucl Med Biol. 2010;37:197-204.
21. Mackenzie B, Erickson JD. Sodium-coupled neutral amino acid (system N/A) transporters of the SLC38 gene family. Pflugers Arch. 2004;447:784-795. (Pubitemid 38241468)
22. +-dependent neutral amino acid transporter. J Biol Chem. 1996;271:14883-14890.
23. + with the sodium-coupled neutral amino acid transporter SNAT2. J Biol Chem. 2008;283:12284-12292.
24. Hatanaka T, Huang W, Wang H, et al. Primary structure, functional characteristics and tissue expression pattern of human ATA2, a subtype of amino acid transport system A. Biochim Biophys Acta. 2000;1467:1-6. (Pubitemid 30621579)
25. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?. Semin Cancer Biol. 2005;15:254-266. (Pubitemid 41065034)
26. 0+. J Biol Chem. 1999;274:23740-23745.
27. Bröer A, Klingel K, Kowalczuk S, Rasko JE, Cavanaugh J, Bröer S. Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup disorder. J Biol Chem. 2004;279:24467-24476. (Pubitemid 38725311)
28. 0AT2). Biochem J. 2006; 393:421-430.
29. Witte D, Ali N, Carlson N, Younes M. Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res. 2002;22:2555-2557.
30. Berlinguet L, Begin N, Babineau LM, Laferte RO. Biochemical studies of an unnatural and antitumor amino acid: 1-aminocyclopentanecarboxylic acid. II. Effects on cellular respiration and amino acid metabolism Can J Biochem Physiol. 1962;40:433-436.